NCT01146171View on ClinicalTrials.gov

Japanese Phase 1 Study of BMS-844203 (CT322)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Neoplasms
Interventions
DRUG

BMS-844203 (CT-322)

Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent

Trial Locations (1)

5898511

Local Institution, Osaka-Sayama-Shi

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY